38,355,684 Shares in ADMA Biologics Inc $ADMA Bought by BlackRock Inc.

Key Points

• BlackRock acquired 38.36 million ADMA Biologics shares worth approximately $321 million, giving it a 16.55% stake. Institutional investors collectively own 75.68% of the company.
• Analyst sentiment is mixed: ADMA has a consensus “Hold” rating and an average price target of $18.67, with recent targets ranging from $17 to $18 and ratings spanning Buy to Strong Sell.
• ADMA shares opened at $9.63, well below their one-year high of $20.46. The company met quarterly EPS expectations at $0.16, while revenue rose 2% year over year to $124.39 million.

BlackRock Inc. acquired a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 38,355,684 shares of the biotechnology company's stock, valued at approximately $321,037,000. BlackRock Inc. owned about 16.55% of ADMA Biologics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Royal Bank of Canada raised its position in ADMA Biologics by 112.7% during the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company's stock valued at $1,903,000 after purchasing an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of ADMA Biologics by 59.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company's stock worth $16,201,000 after acquiring an additional 305,064 shares during the last quarter. Norges Bank purchased a new position in shares of ADMA Biologics during the 2nd quarter worth about $549,000. Finally, EverSource Wealth Advisors LLC grew its holdings in ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 2,180 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ADMA has been the topic of a number of recent analyst reports. Mizuho reduced their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 15th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Zacks Research downgraded ADMA Biologics from a "hold" rating to a "strong sell" rating in a report on Tuesday, August 4th. Canaccord Genuity Group cut their price objective on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 7th. Finally, Wall Street Zen downgraded ADMA Biologics from a "buy" rating to a "hold" rating in a research report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $18.67.

ADMA Biologics Stock Down 0.9%

NASDAQ:ADMA opened at $9.63 on Thursday. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $20.46. The company has a 50-day moving average of $9.03 and a 200 day moving average of $10.60. The firm has a market cap of $2.16 billion, a PE ratio of 13.76 and a beta of 0.74. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts' consensus estimates of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same quarter last year, the firm posted $0.14 EPS. The company's revenue for the quarter was up 2.0% on a year-over-year basis. As a group, research analysts anticipate that ADMA Biologics Inc will post 0.78 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source